Status:
COMPLETED
Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis
Lead Sponsor:
Eisai Co., Ltd.
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
Brief Summary
To investigate the safety and efficacy of the administration of Iguratimod (CRM01T) for 52 weeks in patients with rheumatoid arthritis in clinical practice
Eligibility Criteria
Inclusion
- Inclusion criteria
- Participants with rheumatoid arthritis
- Participants who take iguratimod
- Exclusion criteria
- Participants registered for this survey previously
- Pregnant women or women suspected of being pregnant
- Participants with a serious liver disorder
- Participants with peptic ulcer
- Participants with known hypersensitivity to iguratimod or any of its excipients
Exclusion
Key Trial Info
Start Date :
September 12 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 13 2014
Estimated Enrollment :
2747 Patients enrolled
Trial Details
Trial ID
NCT01850966
Start Date
September 12 2012
End Date
April 13 2014
Last Update
November 5 2018
Active Locations (453)
Enter a location and click search to find clinical trials sorted by distance.
1
Aisai, Aichi-ken, Japan
2
Ama, Aichi-ken, Japan
3
Anjo, Aichi-ken, Japan
4
Chita, Aichi-ken, Japan